Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 103

    1.

    Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

    Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A.

    Breast Cancer Res. 2010;12(3):R26. Epub 2010 May 10.

    PMID:
    20459744
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

    Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain.

    Ann Oncol. 2003 Jun;14(6):833-42. Review.

    PMID:
    12796019
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.

    Pierga JY, Mouret E, Diéras V, Laurence V, Beuzeboc P, Dorval T, Palangié T, Jouve M, Vincent-Salomon A, Scholl S, Extra JM, Asselain B, Pouillart P.

    Br J Cancer. 2000 Dec;83(11):1480-7.

    PMID:
    11076657
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.

    Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L.

    Breast Cancer Res Treat. 2009 Aug;116(3):509-20. Epub 2008 Nov 20.

    PMID:
    19020972
    [PubMed - indexed for MEDLINE]
    5.

    Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.

    Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK.

    Cancer. 2000 Dec 15;89(12):2521-6.

    PMID:
    11135211
    [PubMed - indexed for MEDLINE]
    6.

    Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.

    Quintela-Fandino M, López JM, Hitt R, Gamarra S, Jimeno A, Ayala R, Hornedo J, Guzman C, Gilsanz F, Cortés-Funes H.

    J Clin Oncol. 2006 Aug 1;24(22):3611-8.

    PMID:
    16877728
    [PubMed - indexed for MEDLINE]
    7.

    Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.

    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.

    Jpn J Clin Oncol. 2005 Sep;35(9):514-9.

    PMID:
    16199422
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

    Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G.

    J Clin Oncol. 1996 Apr;14(4):1136-45.

    PMID:
    8648368
    [PubMed - indexed for MEDLINE]
    9.

    Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

    BMC Cancer. 2007 Apr 12;7:63.

    PMID:
    17430582
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?

    Fumoleau P, Bonneterre J, Luporsi E.

    J Clin Oncol. 2003 Mar 15;21(6):1190-1; author reply 1191-2. No abstract available.

    PMID:
    12637489
    [PubMed - indexed for MEDLINE]
    12.

    Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.

    Livi L, Saieva C, Borghesi S, De Luca Cardillo C, Scotti V, Mangoni M, Greto D, Cataliotti L, Paiar F, Bianchi S, Biti GP.

    J Chemother. 2009 Nov;21(5):558-65.

    PMID:
    19933048
    [PubMed - indexed for MEDLINE]
    13.

    Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.

    Stemmer SM, Hardan I, Raz H, Adamou AK, Inbar M, Gottfried M, Merrick Y, Cohen Y, Sulkes A, Ben-Baruch N, Pfeffer RP, Brenner HJ, Rizel S.

    Bone Marrow Transplant. 2003 Apr;31(8):655-61.

    PMID:
    12692605
    [PubMed - indexed for MEDLINE]
    14.

    Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

    Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN.

    Breast J. 2002 Jan-Feb;8(1):2-9.

    PMID:
    11856154
    [PubMed - indexed for MEDLINE]
    15.

    Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study.

    Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD.

    J Clin Oncol. 1998 Jul;16(7):2382-91.

    PMID:
    9667255
    [PubMed - indexed for MEDLINE]
    16.

    In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort".

    DeMichele A, Gimotty P, Botbyl J, Aplenc R, Colligon T, Foulkes AS, Rebbeck TR.

    J Clin Oncol. 2007 Dec 10;25(35):5675-7. No abstract available.

    PMID:
    18065748
    [PubMed - indexed for MEDLINE]
    17.

    Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.

    Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J; Anglo-Celtic Cooperative Oncology Group.

    J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83.

    PMID:
    15265969
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.

    Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W, et al.

    J Clin Oncol. 1993 Mar;11(3):454-60.

    PMID:
    8445420
    [PubMed - indexed for MEDLINE]
    19.

    Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.

    Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM.

    J Clin Oncol. 2011 Mar 20;29(9):1110-6. Epub 2011 Feb 7.

    PMID:
    21300930
    [PubMed - indexed for MEDLINE]
    20.

    Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.

    Wolowacz SE, Cameron DA, Tate HC, Bagust A.

    J Clin Oncol. 2008 Feb 20;26(6):925-33.

    PMID:
    18281666
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk